BHC on XNYS, Health Care, Bausch Health Companies Inc, job postings
Measures activity, not value. Not investment advice.
Revenue rose 11% to $11.1B over twelve months but net loss reached $841M.
GoodFree cash flow reached $1.9B over the last twelve months
WatchDebt of $20.6B against $2.5B cash on the latest balance sheet
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
expected around 12 Jan 2027 (an estimate: a year ago it reported on 13 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $2.9B, net income $436.0M.
31 Dec 2021RevenueNet incomeNet losstallest bar $2.9B30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$2.9B
$436.0M
30 Jun 2026
$2.9B
$258.0M
31 Mar 2026
$2.5B
-$1.4B
31 Dec 2025
$2.8B
-$112.0M
30 Sep 2025
$2.7B
$179.0M
30 Jun 2025
$2.5B
$148.0M
31 Mar 2025
$2.3B
-$58.0M
31 Dec 2024
$2.6B
$93.0M
30 Sep 2024
$2.5B
-$85.0M
30 Jun 2024
$2.4B
$10.0M
31 Mar 2024
$2.2B
-$64.0M
31 Dec 2023
$2.4B
-$39.0M
30 Sep 2023
$2.2B
-$378.0M
30 Jun 2023
$2.2B
$26.0M
31 Mar 2023
$1.9B
-$201.0M
31 Dec 2022
$2.2B
-$410.0M
30 Sep 2022
$2.0B
$399.0M
30 Jun 2022
$2.0B
-$145.0M
31 Mar 2022
$1.9B
-$69.0M
31 Dec 2021
$2.2B
$69.0M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$11.1B
$10.0B
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+11%
+11%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$841.0M
$362.0M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$2.29
$0.97
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
73.2%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
11.2%
18.9%
-25.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
-7.6%
3.6%
-18.2%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
–
-58.8%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
$1.9B
$1.1B
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$2.5B
$1.3B
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$20.6B
$21.0B
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
$18.2B
$19.7B
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
–
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
–
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
19.3
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
0.28
5.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
1.9
5.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
–
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
–
No data for this company
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+3.6%
228 13F filers vs 220
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
60%
223.6M shares held by 13F filers (30 Sep 2026) of 374.3M outstanding (23 Oct 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
2.0%
7.4M shares sold short (30 Oct 2026) of 374.3M outstanding (23 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
1.2
7.4M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-10%
8.2M shares sold short in the report before, 7.4M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
31%
31% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 42%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
–
We do not track this company's careers site yet.
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
We do not track this company's careers site yet.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
+9.7%
$2.9B vs $2.7B (quarter ended 30 Sep 2026)
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
-27%
$66.0M vs $91.0M (quarter ended 30 Sep 2026)
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
–
No data for this company
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$610K
4 quarters, $
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
23
23 articles in the last 7 days; its usual week has 5 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
4.6×
23 articles in the last 7 days; its usual week has 5.
Price $8.22 on 20 Nov 2026, +37% over 12 months (12-month range $4.43 to $8.91)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders sold a net $507K in the last 12 months (the 12 months before: $385.0M).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 1 published in the last 12 months, -88% on the 12 months before.Revenue per quarter. Revenue $2.9B in the latest quarter, +9.7% on a year earlier.Capital spending per quarter. Capital spending $66.0M in the latest quarter, -27% on a year earlier.Institutional holders (13F filers). 228 13F filers reported holding it in the latest 13F quarter, +12% on a year earlier.Lobbying spend. Lobbying spend: $610K published in the last 12 months, -31% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.
Quarter ended 31 Dec 2021: $2.2B, -0.8% on a year earlier; public on 24 Feb 2022
Quarter ended 31 Mar 2022: $1.9B, -5.4% on a year earlier; public on 11 May 2022
Quarter ended 30 Jun 2022: $2.0B, -6.3% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $2.0B, -3.1% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $2.2B, -0.1% on a year earlier; public on 24 Feb 2023
Quarter ended 31 Mar 2023: $1.9B, +1.4% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $2.2B, +10% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $2.2B, +9.4% on a year earlier; public on 3 Nov 2023
Quarter ended 31 Dec 2023: $2.4B, +9.8% on a year earlier; public on 23 Feb 2024
Quarter ended 31 Mar 2024: $2.2B, +11% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $2.4B, +11% on a year earlier; public on 2 Aug 2024
Quarter ended 30 Sep 2024: $2.5B, +12% on a year earlier; public on 1 Nov 2024
Quarter ended 31 Dec 2024: $2.6B, +6.3% on a year earlier; public on 21 Feb 2025
Quarter ended 31 Mar 2025: $2.3B, +4.9% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $2.5B, +5.3% on a year earlier; public on 1 Aug 2025
Quarter ended 30 Sep 2025: $2.7B, +6.8% on a year earlier; public on 31 Oct 2025
Quarter ended 31 Dec 2025: $2.8B, +9.3% on a year earlier; public on 20 Feb 2026
Quarter ended 31 Mar 2026: $2.5B, +12% on a year earlier; public on 1 May 2026
Quarter ended 30 Jun 2026: $2.9B, +13% on a year earlier; public on 31 Jul 2026
Quarter ended 30 Sep 2026: $2.9B, +9.7% on a year earlier; public on 30 Oct 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $78.0M, -2.5% on a year earlier; public on 24 Feb 2022
Quarter ended 31 Mar 2022: $46.0M, -30% on a year earlier; public on 11 May 2022
Quarter ended 30 Jun 2022: $52.0M, -16% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $54.0M, -14% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $66.0M, -15% on a year earlier; public on 24 Feb 2023
Quarter ended 31 Mar 2023: $47.0M, +2.2% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $28.0M, -46% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $42.0M, -22% on a year earlier; public on 3 Nov 2023
Quarter ended 31 Dec 2023: $98.0M, +48% on a year earlier; public on 23 Feb 2024
Quarter ended 31 Mar 2024: $82.0M, +74% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $78.0M, +179% on a year earlier; public on 2 Aug 2024
Quarter ended 30 Sep 2024: $71.0M, +69% on a year earlier; public on 1 Nov 2024
Quarter ended 31 Dec 2024: $106.0M, +8.2% on a year earlier; public on 21 Feb 2025
Quarter ended 31 Mar 2025: $115.0M, +40% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $99.0M, +27% on a year earlier; public on 1 Aug 2025
Quarter ended 30 Sep 2025: $91.0M, +28% on a year earlier; public on 31 Oct 2025
Quarter ended 31 Dec 2025: $92.0M, -13% on a year earlier; public on 20 Feb 2026
Quarter ended 31 Mar 2026: $109.0M, -5.2% on a year earlier; public on 1 May 2026
Quarter ended 30 Jun 2026: $77.0M, -22% on a year earlier; public on 31 Jul 2026
Quarter ended 30 Sep 2026: $66.0M, -27% on a year earlier; public on 30 Oct 2026
Institutional holders (13F filers)
31 Dec 2021 report: 339; public on 14 Feb 2022
31 Mar 2022 report: 343; public on 16 May 2022
30 Jun 2022 report: 306; public on 15 Aug 2022
30 Sep 2022 report: 259; public on 14 Nov 2022
31 Dec 2022 report: 240; public on 14 Feb 2023
31 Mar 2023 report: 217; public on 15 May 2023
30 Jun 2023 report: 212; public on 14 Aug 2023
30 Sep 2023 report: 202; public on 14 Nov 2023
31 Dec 2023 report: 221; public on 14 Feb 2024
31 Mar 2024 report: 223; public on 15 May 2024
30 Jun 2024 report: 220; public on 14 Aug 2024
30 Sep 2024 report: 201; public on 14 Nov 2024
31 Dec 2024 report: 216; public on 14 Feb 2025
31 Mar 2025 report: 220; public on 15 May 2025
30 Jun 2025 report: 202; public on 14 Aug 2025
30 Sep 2025 report: 204; public on 14 Nov 2025
31 Dec 2025 report: 228; public on 17 Feb 2026
31 Mar 2026 report: 223; public on 15 May 2026
30 Jun 2026 report: 220; public on 14 Aug 2026
30 Sep 2026 report: 228; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $120K published
Quarter from 1 Apr 2022: $240K published
Quarter from 1 Jul 2022: $120K published
Quarter from 1 Oct 2022: $130K published
Quarter from 1 Jan 2023: $130K published
Quarter from 1 Apr 2023: $190K published
Quarter from 1 Jul 2023: $120K published
Quarter from 1 Oct 2023: $180K published
Quarter from 1 Jan 2024: $170K published
Quarter from 1 Apr 2024: $300K published
Quarter from 1 Jul 2024: $190K published
Quarter from 1 Oct 2024: $190K published
Quarter from 1 Jan 2025: $190K published
Quarter from 1 Apr 2025: $310K published
Quarter from 1 Jul 2025: $190K published
Quarter from 1 Oct 2025: $190K published
Quarter from 1 Jan 2026: $190K published
Quarter from 1 Apr 2026: $360K published
Quarter from 1 Jul 2026: $30K published
Quarter from 1 Oct 2026: $30K published
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is lobbying spend reported (quarter) at $30K (30 Sep 2026), 84% below its normal reading of $190K; higher than 49% of its own history.
Reported lobbying spend: $30K in Q3 2026, $30K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
31 Mar 2026
Ended
Bausch Health Companiesits own lobbyists
General issues related to health care and pharmaceuticals; drug pricing; patent reform; Medicare issues, including drug price negotiations; FDA issues; FTC issues; H.R.8267 - Old Drugs, New Cures ActHealth issues
Public Strategies Washington, Inc.for Bausch Health Companies, Inc.
Proposals impacting the prescription drug industry, including issues relating to prescription drug pricing, oversight, patents, and intellectual property in Medicare and generally. Issues relating to biologics and biosimilars in Medicare and generally.Medicare/Medicaid, Health issues
Two or more unrelated kinds of records unusual within 30 days
25 Feb 2020confirmed
Confirmed across sources Attention and Insiders and Lobbying and Short interest and volume
Bausch Health Companies(BHC): had 19.8M shares sold short in the 31 Jan 2020 report, 1.8× the same report last year; it also drew 6,767 Wikipedia page views in the week of 17 Feb 2020, 1.5× the same week last year; it also had 3 insiders buy $285K of its shares on the open market within 30 days (3 filings); and it reported $380K of lobbying spend for the quarter ended 31 Mar 2020, 1.1× the same quarter last year. Four unrelated kinds of activity within 105 days.
Short interest and volume: Short interest spike, became public on 28 Jan 2020
Short interest and volume: Short interest spike, became public on 12 Feb 2020
Attention: Wikipedia attention spike, became public on 25 Feb 2020
Short interest and volume: Short interest spike, became public on 27 Feb 2020
Insiders: Clustered insider buying, became public on 12 Mar 2020
Short interest and volume: Short interest spike, became public on 11 Mar 2020
Short interest and volume: Short interest spike, became public on 25 Mar 2020
Lobbying: Lobbying spend jump, became public on 8 Apr 2020
Short interest and volume: Short interest spike, became public on 10 Apr 2020
Short interest and volume: Short interest spike, became public on 25 Apr 2020
Short interest and volume: Short interest spike, became public on 12 May 2020
The 31 Jan 2020 report against the 24 reports before it.
this reportearliernormal: 10.7MSee the evidence (11 changes)
Short interest and volume: Short interest spike became public on 28 Jan 2020
Bausch Health Companies had 18.2M shares sold short in the 15 Jan 2020 report, 1.7× the same report last year.
This period
18.2M (the 15 Jan 2020 report)
Normal report (median of 24 earlier)
10.7M
Typical spread (median absolute deviation)
598K
How far from its usual level
+7.1
Same report last year
10.7M
History used
533 days
the 15 Jan 2020 report24 earlier reportsnormal: 10.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Feb 2020
Bausch Health Companies had 19.8M shares sold short in the 31 Jan 2020 report, 1.8× the same report last year.
This period
19.8M (the 31 Jan 2020 report)
Normal report (median of 24 earlier)
10.7M
Typical spread (median absolute deviation)
665K
How far from its usual level
+8.5
Same report last year
10.7M
History used
549 days
the 31 Jan 2020 report24 earlier reportsnormal: 10.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Attention: Wikipedia attention spike became public on 25 Feb 2020
Bausch Health Companies drew 6,767 Wikipedia page views in the week of 17 Feb 2020, 1.5× the same week last year.
This period
6,767 (the week of 17 Feb 2020)
Normal week (median of 26 earlier)
3,438
Typical spread (median absolute deviation)
306
How far from its usual level
+7.3
Same week last year
4,586
History used
418 days
the week of 17 Feb 202026 earlier weeksnormal: 3,438
Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.
Short interest and volume: Short interest spike became public on 27 Feb 2020
Bausch Health Companies had 20.2M shares sold short in the 14 Feb 2020 report, 2.2× the same report last year.
This period
20.2M (the 14 Feb 2020 report)
Normal report (median of 24 earlier)
10.7M
Typical spread (median absolute deviation)
834K
How far from its usual level
+7.6
Same report last year
9.3M
History used
563 days
the 14 Feb 2020 report24 earlier reportsnormal: 10.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
Short interest and volume: Short interest spike became public on 11 Mar 2020
Bausch Health Companies had 20.0M shares sold short in the 28 Feb 2020 report, 1.8× the same report last year.
This period
20.0M (the 28 Feb 2020 report)
Normal report (median of 24 earlier)
10.8M
Typical spread (median absolute deviation)
945K
How far from its usual level
+6.6
Same report last year
10.9M
History used
577 days
the 28 Feb 2020 report24 earlier reportsnormal: 10.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Mar 2020
Bausch Health Companies had 23.0M shares sold short in the 13 Mar 2020 report, 2.4× the same report last year.
This period
23.0M (the 13 Mar 2020 report)
Normal report (median of 24 earlier)
10.8M
Typical spread (median absolute deviation)
1.1M
How far from its usual level
+7.7
Same report last year
9.6M
History used
591 days
the 13 Mar 2020 report24 earlier reportsnormal: 10.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Lobbying: Lobbying spend jump became public on 8 Apr 2020
Bausch Health Companies reported $380K of lobbying spend for the quarter ended 31 Mar 2020, 1.1× the same quarter last year.
This period
$380K (the quarter ended 31 Mar 2020)
Normal quarter (median of 8 earlier)
$159K
Typical spread (median absolute deviation)
$36K
How far from its usual level
+4.1
Same quarter last year
$350K
History used
3,288 days
the quarter ended 31 Mar 20208 earlier quartersnormal: $159K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.
Short interest and volume: Short interest spike became public on 10 Apr 2020
Bausch Health Companies had 23.5M shares sold short in the 31 Mar 2020 report, 2.6× the same report last year.
This period
23.5M (the 31 Mar 2020 report)
Normal report (median of 24 earlier)
11.0M
Typical spread (median absolute deviation)
1.1M
How far from its usual level
+7.8
Same report last year
9.0M
History used
609 days
the 31 Mar 2020 report24 earlier reportsnormal: 11.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Apr 2020
Bausch Health Companies had 21.3M shares sold short in the 15 Apr 2020 report, 2.4× the same report last year.
This period
21.3M (the 15 Apr 2020 report)
Normal report (median of 24 earlier)
11.0M
Typical spread (median absolute deviation)
1.1M
How far from its usual level
+6.3
Same report last year
9.0M
History used
624 days
the 15 Apr 2020 report24 earlier reportsnormal: 11.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 May 2020
Bausch Health Companies had 19.6M shares sold short in the 30 Apr 2020 report, 1.8× the same report last year.
This period
19.6M (the 30 Apr 2020 report)
Normal report (median of 24 earlier)
11.2M
Typical spread (median absolute deviation)
1.1M
How far from its usual level
+5.1
Same report last year
10.9M
History used
639 days
the 30 Apr 2020 report24 earlier reportsnormal: 11.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
1 Jul 2026Filings change
filed a director or officer change (8-K item 5.02), its first in 90 days.
Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.
saw 44 13F filers open a new position in the quarter ended 31 Dec 2025, 1.4× the same quarter last year.
Same quarter last year: 31; its normal quarter is 30.5.
See the evidence
This period
44 (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
30.5
Typical spread (median absolute deviation)
2
How far from its usual level
+4.4
Same quarter last year
31
History used
2,741 days
the quarter ended 31 Dec 20258 earlier quartersnormal: 30.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
reported $280K of lobbying spend for the quarter ended 31 Mar 2025, 6.7% below the same quarter last year.
Same quarter last year: $300K; its normal quarter is $190K.
See the evidence
This period
$280K (the quarter ended 31 Mar 2025)
Normal quarter (median of 8 earlier)
$190K
Typical spread (median absolute deviation)
$5K
How far from its usual level
+4.5
Same quarter last year
$300K
History used
5,844 days
the quarter ended 31 Mar 20258 earlier quartersnormal: $190K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.
spent $82.0M on capital projects in the quarter ended 31 Mar 2024, 1.7× the same quarter last year.
Same quarter last year: $47.0M; its normal quarter is $49.5M.
See the evidence
This period
$82.0M (the quarter ended 31 Mar 2024)
Normal quarter (median of 8 earlier)
$49.5M
Typical spread (median absolute deviation)
$6.0M
How far from its usual level
+3.7
Same quarter last year
$47.0M
History used
5,388 days
the quarter ended 31 Mar 20248 earlier quartersnormal: $49.5M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Showing the newest 40 of 128 entries; narrow the window or the kind of data to see older ones.
Not listed: 238 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0000885590
Ticker
BHC
Domain
bauschhealth.com
Employer name
Bausch Health, Bausch Health US, LLC, BIOVAIL (3 unverified)
Fein
33-0949894 (1 unverified)
Hq location
A8|QUEBEC|H7L 4 (1 unverified)
Lobbying client
bausch health, bausch health companies, bausch health companies inc f k a valeant pharmaceuticals international, valeant pharmaceuticals
Name
12279967 Canada Ltd, 12283778 Canada Ltd, 1261229 B.C. Ltd, 1375209 B.C. Ltd and 151 more
Wikidata
Q1700871
Wikipedia
Bausch Health
DOL H-1B labor condition applications and PERM certifications67 data points17 Jun 2024 to 9 Feb 2026
Federal lobbying disclosures (LDA)13 records, 218 data points30 Jun 2005 to 30 Sep 2026
SEC Form 13F institutional holdings1 record, 306 data points30 Jun 2018 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)245 records6 Jan 2016 to 28 Oct 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)1108 data points31 Dec 2007 to 23 Oct 2026
SEC Form 4 insider transactions75 records, 252 data points13 Jun 2016 to 20 Aug 2026
FINRA short interest (twice monthly)594 data points31 Jul 2018 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
WARN layoff notices (state labor agencies)1 record, 3 data points27 Nov 2006 to 1 Dec 2006
Wikipedia pageviews2882 data points1 Jan 2019 to 21 Nov 2026